Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort

Hepa C

Status: Completed

Conditions: Hepatitis C

Treatments: Other: Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir

Study type: Observational

Funder types: Other

Identifiers

NCT03111966

0001

Details and patient eligibility

About

This is a multicentre, descriptive, observational and ambispective study carried out in patients who are treated with Elbasvir/Grazoprevir in hospitals that included their data in Hepa-C Registry (directed by the Spanish Association for the Study of the Liver and the Networked Biomedical Research Centre for Hepatic and Digestive Diseases).

Full description

This is a multicentre, descriptive, observational and ambispective study carried out in patients who are treated with Elbasvir/Grazoprevir in hospitals that included their data in Hepa-C Registry (directed by the Spanish Association for the Study of the Liver and the Networked Biomedical Research Centre for Hepatic and Digestive Diseases)

Enrollment: 130 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age: 18 years to 100 years (adult).
• Sexes: all
• Healthy volunteers: no
• Chronic hepatitis C (anti-HCV antibodies and detectable HCV-RNA).

Exclusion criteria

Trial design

130 participants in 1 patient group

Spanish cohort with HCV treated with DAA

Treatment:

Other: Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir